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To the Editor: Mutations in HNF4A, which encodes hepatocyte
nuclear factor-4 α, cause maturity-onset diabetes of the young
(MODY) [1].HNF4A-MODY is also associated with congenital
hyperinsulinism (CHI) and neonatal hypoglycaemia [2]. Our
understanding of the transition from hyperinsulinism to diabetes
is limited. One hypothesis is higher fetal insulin secretion triggers
apoptosis and results in accelerated postnatal beta cell failure.
Alternatively, HNF4A deficiency could cause distinct transcrip-
tional defects in early and late life, leading to the contrasting
insulin phenotypes [2, 3]. These two hypotheses differ as to
whether hypersecretion of insulin in utero precipitates beta cell
failure later in life.
Fetal insulin secretion is known to be a major determinant
of birthweight, particularly in humans [4, 5]. Our analysis of
individuals with complete absence of fetal insulin secretion,
due to mutations in the insulin gene or pancreatic agenesis,
have shown they are half the normal birthweight [5].
Additionally, in individuals with HNF4A mutations,
macrosomia has been reported as always occurring in those
with neonatal hyperinsulinaemic hypoglycaemia [2]. Thus,
birthweight may be a useful bioassay of fetal insulin secretion.
In this study we sought to determine the association between
birthweight and penetrance of diabetes in individuals with
HNF4Amutations, which could provide insights into the rela-
tionship between fetal and adult insulin secretory capacity.
Data from genetic testing referral forms was extracted for all
individuals with birthweight data and a rare (absent from
gnomAD v2.1.1 [5]) pathogenic HNF4A mutation (Molecular
Genetics laboratory, Exeter, UK [n = 204], and Motol
University Hospital, Prague, Czech Republic [n = 59]). Due to
a lack of population-level sequencing data, which is needed to
confidently define variant penetrance and pathogenicity, we then
excluded a small number of individuals self-reported as non-
White (n = 7). Individuals aged <7 years at study (n = 63) were
also removed due to lack of diabetes presenting. Finally, for accu-
rate determination of corrected birthweight, a small number of
individuals self-reported as a twin (n = 4) or born ≤32 weeks
gestation (n = 3) were removed. This resulted in the cohort
presented here (n = 186, see electronic supplementary material
[ESM] Table 1 for clinical characteristics). The characteristics of
our cohort meant we calculated we had >80% power to detect a
HR ≥ 1.43 or ≤ 0.70. BMI for children was adjusted to adult
equivalent using the Child Growth Foundation reference stan-
dards [6]. Birthweights were corrected for gestation and sex using
British 1990/UK-WHO growth standards [7] and calculated
using the zanthro package [8]. Statistical analyses were
performed using Stata v16 (StataCorp, Texas, USA). This study
had ethical approval from the North Wales Research Ethics
Committee (17/WA/0327) and Motol University Hospital
Ethics Commitee.
We first sought to assess the impact of maternal diabetes and
an HNF4Amutation on birthweight. The birthweight of individ-
uals with a mutation was higher than that of family members
without the mutation (4.17 kg [IQR = 3.60–4.71], n = 186 vs
3.66 kg [IQR = 3.30–4.18], n = 31; p< 0.001). The results were
similar when analysis was restricted to individuals born to
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mothers not reported to have diabetes (4.03 kg [IQR = 3.64–
4.56], n = 72 vs 3.44 kg [IQR = 3.24–3.85], n = 20; p = 0.001)
(Fig. 1a). Furthermore, for individuals with a mutation, those
born to a mother with diabetes during pregnancy had an even
higher birthweight than those born to a mother never reported to
have diabetes (4.47 kg [IQR = 3.76–4.88], n = 55 vs 4.03 kg
[IQR = 3.64–4.56], n = 72; p = 0.04) (Fig. 1a).
To assess the impact of birthweight on penetrance, we
performed univariable Cox proportional-hazards survival analy-
sis and found each per-kg increase was associated with a 22%
reduction in diabetes diagnoses (HR = 0.78 [95% CI = 0.62,
0.97]; p = 0.03) (Table 1). For those individuals with a
birthweight less than 4.17 kg (cohort median), 50% had devel-
oped diabetes by the age of 22 years, whereas for individuals
with a birthweight more than 4.17 kg, 50% had developed diabe-
tes by the age of 30 years (Fig. 1b). We observed similar results
when analysis was limited to individuals with protein-truncating
variants (HR = 0.64, 95%CI = 0.42, 0.98, p = 0.04), or a likely
paternally inherited mutation (father reported to have diabetes
and/or mutation and mother reported not to have diabetes) (HR
= 0.63, 95% CI = 0.40, 0.99, p = 0.05).
To assess if birthweight is independently associated
with penetrance, we conducted multivariable Cox
proportional-hazards survival analyses adjusting for other
factors affecting penetrance. To identify factors associated
with penetrance of HNF4A-MODY, we compared the
characteristics of individuals with or without diabetes at
20 years of age (median age of diabetes diagnosis for
cohort). Besides lower birthweight, being a proband,
female, and born to a mother with diabetes during preg-
nancy was associated with earlier onset (all p< 0.05)
(ESM Table 2). After adjusting for these variables, the
effect of birthweight on penetrance remained independent,
with each per-kg increase associated with a 30% reduction
in diabetes diagnoses (HR = 0.70 [95% CI = 0.54, 0.91];
p = 0.008, Table 1).
We have found that, amongst individuals with highly pene-





































































Fig. 1 HNF4A mutations are associated with a maternal glucose-inde-
pendent increase in birthweight and a higher birthweight is associated
with relative protection from diabetes. (a) Sex and gestation-corrected
birthweights for individuals with HNF4A mutations, split by presence
of maternal diabetes during pregnancy, and non-carrier relatives. p values
were calculated by Mann–Whitney U tests. The horizontal line within
each box represents the median, and the top and bottom of the box repre-
sent the 75th and 25th percentiles, respectively. The whiskers indicate the
maximum and minimum values, excluding outliers. Filled circles indicate
outliers. (b) Kaplan–Meier plot of survival from diabetes split by median
birthweight for individuals with HNF4A mutations (n = 186)
Table 1 Hazard ratios for factors





HR (95% CI) p HR (95% CI) p
Female 1.40 (1.00, 1.98) 0.053 1.60 (1.09, 2.34) 0.015
Proband 2.47 (1.75, 3.48) <0.001 2.98 (2.02, 4.40) <0.001
Mother with diabetes during pregnancy 2.13 (1.42, 3.19) <0.001 3.07 (2.00, 4.71) <0.001
Corrected birthweight (per kg increase) 0.78 (0.62, 0.97) 0.03 0.70 (0.54, 0.91) 0.008
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reduced penetrance of diabetes. We speculate that this reflects a
correlation between an individual’s fetal and adult insulin secre-
tory capacity, such that there is a lesser reduction in adult beta cell
function for individuals with an HNF4A mutation and a higher
birthweight. Direct measurement of perinatal glucose/insulin
levels and longitudinal studies of beta cell function would enable
firmer mechanistic conclusions, but these studies are inherently
difficult and costly to perform.
We have recently reported that transfer to sulfonylureas is not
universally successful for individuals with HNF4A-MODY, and
that BMI and diabetes duration are predictors of transfer success
[9]. Given the results presented here, we believe studies investi-
gating treatment response with respect to birthweight and
mother’s diabetes status during pregnancy are warranted.
We previously reported a hypomorphic HNF4A missense
mutation (p.R114W) associated with no increase in
birthweight and reduced penetrance [10]. The requirement
for mutations in this cohort to be absent from gnomAD should
have limited the inclusion of individuals with similar, relative-
ly common, hypomorphic mutations. If some hypomorphic
mutations have been included, and act similarly to
p.R114W, then their presence would result in an underestima-
tion of the modifying effect of birthweight on penetrance.
Future analyses of penetrance in population cohorts consisting
of millions of sequenced individuals will be important for
refining the effect size estimate.
In conclusion, this is one of the first and largest studies
investigating the factors affecting penetrance of HNF4A-
MODY, identifying birthweight as a modifier of potential
prognostic and therapeutic relevance.
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